CION Ameerpet
Immunotherapy Side Effects · Heart, Kidney, Muscle & Nerve Reactions
How Rare Are Severe Immune Reactions on Immunotherapy — Really?
Severe (grade 3-4) immune-related side effects are genuinely uncommon on immunotherapy — most reactions are mild. Roughly 10-15% of patients on single-drug immunotherapy, and up to about 40-55% on combination immunotherapy, develop a severe reaction, per NCCN and ASCO safety guidance. This page puts the whole picture in proportion.
Medically reviewed by Dr. C. Raghavendra Reddy, Medical Oncologist, MBBS (Gold Medal) · DNB · DM (Medical Oncology, Gold Medal) · Last reviewed August 2026
- Most reactions are mild — severe reactions are the minority, not the norm, on any immunotherapy regimen.
- Risk depends on your regimen — combination immunotherapy carries a meaningfully higher severe-reaction rate than single-drug treatment.
- Early reporting changes everything — reactions caught in the first days are far easier to treat than ones left unreported for weeks.
- Rare isn't untreatable — steroids and supportive care resolve the large majority of even severe immune reactions.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Read this first
Are You Having Symptoms Right Now? Get Emergency Help First
If you're on immunotherapy and currently have breathlessness, chest pain, severe or bloody diarrhoea, yellowing of the skin or eyes, confusion, or sudden weakness, don't wait for this page's numbers to make sense of it — call for help now. These are exactly the reactions that turn serious fastest, and same-day assessment is what keeps them minor.
Call now, or go to the nearest emergency room, if you have:
- Breathlessness, chest pain, palpitations or an irregular heartbeat
- Severe or bloody diarrhoea, or severe abdominal pain
- Yellowing of the skin or eyes (jaundice)
- New confusion, severe headache, or sudden vision changes
- Sudden weakness, drooping eyelid, or difficulty walking
- Severe weakness with vomiting and dizziness (possible adrenal crisis)
If none of these apply to you right now, read on — the rest of this page puts how common (and how rare) these reactions actually are into proportion.
The real numbers
What Proportion of Patients Actually Get a Severe Reaction?
Severe (grade 3-4) reactions are the minority, not the norm. On single-drug immunotherapy, roughly 10-15% of patients develop a severe reaction; on combination (two-drug) immunotherapy, that rises to roughly 40-55%. The large majority of patients on any regimen experience only mild-to-moderate, manageable side effects, according to NCCN and ASCO immune-related adverse event guidance.
| Regimen | Any-grade reaction | Severe (Grade 3-4) reaction |
|---|---|---|
| Single-drug immunotherapy | Around 70-90% (mostly mild, grade 1-2) | Around 10-15% |
| Combination (two-drug) immunotherapy | Nearly all patients experience some reaction | Around 40-55% |
Ranges reflect figures commonly cited in NCCN and ASCO immunotherapy-toxicity management guidance (current as of 2024-2025). Your individual risk varies by cancer type, overall health, and pre-existing autoimmune conditions — indicative, not a personal prediction.
Did you know? The large majority of patients who develop even a severe immune reaction go on to recover fully with prompt corticosteroid treatment, and many are able to safely resume immunotherapy afterward.
Which reactions
Which Severe Reactions Are Commonest?
Among severe reactions, gut inflammation (colitis) is the commonest, especially with combination immunotherapy. Liver, lung and hormone-gland reactions follow at lower rates. Heart, kidney, nerve and muscle reactions — the ones covered in this cluster — are the rarest of all, but carry a disproportionately higher risk if they're missed or treated late.
| Organ system | How common when severe | Why it matters |
|---|---|---|
| Gut (colitis) | Commonest severe reaction, more so with combination therapy | Can cause dehydration or bowel injury if ignored |
| Liver (hepatitis) | Uncommon | Often silent — caught by routine blood tests, not symptoms |
| Lungs (pneumonitis) | Uncommon | Disproportionately serious because it affects breathing quickly |
| Hormone glands (thyroid, pituitary, adrenal) | Common overall; severe adrenal crisis is rare | Usually manageable long-term with hormone replacement |
| Heart (myocarditis) | Rare | Carries the highest reaction-related fatality risk of any immune reaction |
| Kidneys (nephritis) | Rare | Usually reversible if caught through routine creatinine monitoring |
| Nerves and muscles | Rare | Can progress quickly; treated as a neurological emergency |
Timing matters
When Do Severe Reactions Typically Appear?
Timing is a genuine clue, not a coincidence. Skin and gut reactions tend to appear earliest, while hormone-gland and the rare organ reactions in this cluster can appear at almost any point — including months after stopping — which is why timing alone should never be used to rule a reaction out.
| Reaction type | Typically starts |
|---|---|
| Skin reactions | Weeks 2-6 of treatment |
| Gut (colitis) | Weeks 5-10 of treatment |
| Liver (hepatitis) | Weeks 6-14 of treatment |
| Hormone glands (endocrine) | Any time, often after several months |
| Lungs (pneumonitis) | Median around 2-3 months, but a wide range |
| Heart (myocarditis) | Often within the first 1-2 treatment cycles, though possible later |
| Kidneys, nerves or muscles | Any time during treatment, occasionally after stopping |
What actually helps
What Reduces the Risk of a Severe Reaction?
No screening test eliminates risk, but several things measurably lower it: baseline organ and autoimmune-history screening before starting, sticking to your monitoring blood-test schedule, reporting new symptoms the same day rather than waiting, and prompt steroid treatment the moment a reaction is confirmed. Each step shortens how long a reaction runs unchecked.
- Baseline screening. Your oncology team checks thyroid, liver and kidney function, plus autoimmune history, before you start — to flag added risk early.
- Routine monitoring blood tests. Kept on schedule, not skipped, especially in the early months when most reactions begin.
- Same-day symptom reporting. Waiting "to see if it passes" is the single biggest factor that turns a mild reaction into a severe one.
- Choosing the right regimen. Your oncologist weighs single-drug versus combination immunotherapy against your cancer type and risk profile, not efficacy alone.
- Prompt steroid treatment. Starting corticosteroids as soon as a reaction is confirmed is what keeps most reactions — even initially severe ones — reversible.
12+ Centres in Hyderabad · Pick yours
CION cancer care is closer than you think.
We're never more than 30 minutes away. Same panel of specialists at every centre. Same tumour board reviews. Same NCCN protocols. Pick the closest one and call directly — or let us pick for you.
CION Ameerpet
CION Kukatpally
CION L.B. Nagar
CION Tolichowki
CION Masab Tank
CION Banjara Hills
CION Kompally
CION Balanagar
CION Siddipet
CION Sangareddy
Not sure which centre fits best? Tell us where you are — we'll suggest the closest one with the right specialists.
Help me pick the right centre
Beyond Hyderabad
35+ centres across Telangana & Andhra Pradesh
Travelling for treatment? We may have a centre right where you are.
Telangana
Andhra Pradesh
Don't see your city? Call 18002028726 — we'll find your nearest CION partner centre.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Know Your Real Risk — Don't Guess
Our tumour board includes the same specialists monitoring immunotherapy patients for these exact reactions.
What happens if a reaction is suspected
How Is a Suspected Severe Reaction Actually Confirmed and Treated?
Reporting a symptom early leads to a structured pathway, not guesswork. Because immune-related reactions can overlap across organ systems, a suspected severe reaction is worked up broadly first, then narrowed down and treated based on what's actually found.
- 1
Immediate multi-system screening
Vitals and a symptom timeline covering gut, liver, lung, hormone, heart and nerve systems together, since reactions in this group often overlap.
- 2
Grading against a standard scale
Clinicians grade the reaction from mild to severe using standard toxicity criteria, which decides whether immunotherapy continues, pauses, or stops.
- 3
Targeted tests
Blood work such as liver enzymes, creatinine, cardiac troponin and a thyroid panel, plus imaging if needed, chosen based on which organ system is suspected.
- 4
Corticosteroids as first-line treatment
Most confirmed severe reactions are treated with high-dose steroids first, then tapered gradually once the reaction settles.
- 5
Escalation to specialty care
Cardiology, neurology, nephrology or gastroenterology join the oncology team when the reaction involves their organ system.
- 6
A shared decision on restarting immunotherapy
Once the reaction has resolved or stabilised, your oncology team weighs its severity against your cancer's need for continued treatment before deciding whether and how to restart.
Care during treatment
Severe Reactions Are Rare — and Manageable When Caught Early
Patients who report new symptoms promptly are supported by the same multidisciplinary team throughout treatment.
Real Stories. Real Voices.
15,000+ patients chose CION. Hear from them directly.
These aren't paid endorsements or written reviews. These are video testimonials from real patients and families — recorded on their own phones, in their own words. Pick any one. Watch it. Then decide.
4.8★800+ Google reviews
50+video testimonials
15,000+patients treated
Read all 800+ reviews on Google
Start Your Story. Book Free Consultation.
Common questions
How Common Are Severe Immune Reactions? Your Questions Answered
What proportion of immunotherapy patients actually get a severe reaction?
Severe (grade 3-4) immune-related reactions are the minority, not the norm. On single-drug immunotherapy, roughly 10-15% of patients develop a severe reaction; on combination (two-drug) immunotherapy, that rises to roughly 40-55%, according to NCCN and ASCO immune-related adverse event management guidance. The large majority of patients on any regimen experience only mild-to-moderate side effects that are managed without stopping treatment.
Which severe immune-related reactions are the commonest?
Among severe reactions, gut inflammation (colitis) is the commonest, especially with combination immunotherapy, followed by liver, lung and hormone-gland reactions at lower rates. Heart, kidney, nerve and muscle reactions — the ones covered in this cluster of pages — are the rarest of all severe reactions, but carry a disproportionately higher risk if they are missed or treated late, which is why they are handled as same-day emergencies.
What actually reduces the risk of a severe immune reaction?
No screening test eliminates risk entirely, but several things measurably lower it: baseline organ and autoimmune-history screening before you start, staying on schedule with monitoring blood tests, reporting new symptoms the same day rather than waiting to see if they pass, and prompt corticosteroid treatment the moment a reaction is confirmed. Each step shortens how long a reaction runs unchecked, which is the main driver of how severe it becomes.
Does combination immunotherapy carry more risk than single-drug treatment?
Yes. Combination (two-drug) immunotherapy is more effective for some cancers, but it also raises the rate of severe reactions considerably compared with single-drug treatment — roughly 40-55% versus roughly 10-15%, per NCCN and ASCO guidance. This trade-off is exactly why your oncologist weighs your specific cancer type and risk factors before recommending one regimen over the other, rather than defaulting to combination therapy for everyone.
Are severe immune-related reactions ever fatal?
Life-threatening immune-related reactions are recognised in only a small minority of patients treated with immunotherapy, most often linked to heart, lung or nerve involvement, and prompt recognition substantially lowers this risk further. This is exactly why heart, kidney, muscle and nerve reactions — the rarest reactions overall — are still treated as same-day emergencies rather than routine follow-up concerns.
If I've had one severe reaction, can I safely continue immunotherapy?
In many cases, yes. Once a severe reaction has resolved or stabilised on treatment such as steroids, your oncology team weighs the reaction's cause and severity against your cancer's need for continued treatment before deciding whether and how to restart. Some reactions mean immunotherapy is paused permanently for that specific drug, while others allow a cautious, closely monitored restart — this decision is always made case by case, not by a fixed rule.